• 2181 Citations
  • 20 h-Index
20042020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2020

Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes

Molga, A., Wall, M., Chhetri, R., Wee, L. Y., Singhal, D., Edwards, S., Singhal, N., Ross, D., To, L. B., Caughey, G., Shakib, S., Germing, U., To, T. & Hiwase, D., 1 Jan 2020, In : Journal of Geriatric Oncology. 11, 1, p. 114-120 7 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., Carne, L., Rwodzi, Z., Watts, S., McLean, J., Braley, J., Altamura, H., Yeung, D. T., Branford, S., Yong, A. S. M., White, D. L., Hughes, T. P. & Ross, D. M., Apr 2020, In : Leukemia. 34, 4, p. 1052-1061 10 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Use of romiplostim in pregnancy for refractory idiopathic thrombocytopenic purpura: Two case reports with maternal and fetal outcomes and literature review

Chua, S. J., Morton, M. R., Svigos, J., Ross, D. M. & Kane, S., 1 Mar 2020, In : Obstetric Medicine. 13, 1, p. 45-50 6 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)
2019

Asciminib in chronic myeloid leukemia after Abl kinase inhibitor failure

Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y. T., Talpaz, M., Hochhaus, A., Coutre, P. L., Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F. X., Minami, Y., Yeung, D., Ross, D. M. & 10 others, Tallman, M. S., Park, J. H., Druker, B. J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K. G., Lang, F. & Kim, D. W., 12 Dec 2019, In : New England Journal of Medicine. 381, 24, p. 2315-2326 12 p.

Research output: Contribution to journalArticle

20 Citations (Scopus)

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

Lasica, M., Willcox, A., Burbury, K., Ross, D. M., Branford, S., Butler, J., Filshie, R., Januszewicz, H., Joske, D., Mills, A., Simpson, D., Tam, C., Taylor, K., Watson, A. M., Wolf, M. & Grigg, A., 7 Jun 2019, In : Leukemia and Lymphoma. 60, 7, p. 1796-1802 7 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)
2018

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., Kan, W. L., Hercus, T. R., Stomski, F., Hughes, T., Tergaonkar, V., Parker, M. W., Ross, D. M., Majeti, R., Babon, J. J. & Lopez, A. F., 28 Nov 2018, In : Science Advances. 4, 11, eaat3834.

Research output: Contribution to journalArticle

7 Citations (Scopus)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., Braley, J., White, D. L., Yeung, D. T., Branford, S., Hughes, T. P. & Ross, D. M., 30 Nov 2018, In : Haematologica. 103, 12, p. 2026-2032 7 p.

Research output: Contribution to journalArticle

Open Access
13 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., 1 May 2018, In : Journal of Cancer Research and Clinical Oncology. 144, 5, p. 945-954 10 p.

Research output: Contribution to journalArticle

43 Citations (Scopus)

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Branford, S., Wang, P., Yeung, D., Thomson, D., Purins, A., Wadham, C., Shahrin, N. H., Marum, J. E., Nataren, N., Parker, W. T., Geoghegan, J., Feng, J., Shanmuganathan, N., Mueller, M. C., Dietz, C., Stangl, D., Donaldson, Z., Altamura, H., Georgievski, J., Braley, J. & 13 others, Brown, A., Hahn, C., Walker, I., Kim, S. H., Choi, S. Y., Park, S. H., Kim, D. W., White, D., Yong, A., Ross, D. M., Scott, H. S., Schreiber, A. W. & Hughes, T., 30 Aug 2018, In : Blood. 132, 9, p. 948-961 14 p.

Research output: Contribution to journalArticle

35 Citations (Scopus)

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG), 1 Dec 2018, In : Leukemia. 32, 12, p. 2572-2579 8 p.

Research output: Contribution to journalArticle

14 Citations (Scopus)

Patient perceptions of treatment-free remission in chronic myeloid leukemia

Villemagne Sanchez, L. A., O’Callaghan, C., Gough, K., Hall, K., Kashima, Y., Seymour, J. F., Schofield, P. & Ross, D., 1 Feb 2018, In : Leukemia and Lymphoma. 59, 2, p. 406-415 10 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)
2017

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis

Ho, P. J., Bajel, A., Burbury, K., Dunlop, L., Durrant, S., Forsyth, C., Perkins, A. C. & Ross, D. M., 1 Mar 2017, In : Internal Medicine Journal. 47, 3, p. 262-268 7 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm

Casolari, D. A., Nguyen, T., Butcher, C. M., Iarossi, D. G., Hahn, C. N., Bray, S. C., Neufing, P. J., Parker, W. T., Feng, J., Maung, K. Z. Y., Wee, A., Vidovic, L., Kok, C. H., Bardy, P. G., Branford, S., Lewis, I. D., Lane, S. W., Scott, H. S., Ross, D. M. & D'Andrea, R. J., 1 Dec 2017, In : Scientific Reports. 7, 1, 2467.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

Douglas, G., Harrison, C., Forsyth, C., Bennett, M., Stevenson, W., Hounsell, J., Ratnasingam, S., Ritchie, D., Ross, D. M. & Grigg, A., 2 Jan 2017, In : Leukemia and Lymphoma. 58, 1, p. 89-95 7 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients

Hiwase, D., Singhal, D., Strupp, C., Chhetri, R., Kutyna, M. M., Wee, L. A., Harrison, P. B., Nath, S. V., Wickham, N., Hui, C. H., Gray, J. X., Bardy, P., Ross, D. M., Lewis, I. D., Reynolds, J., To, L. B. & Germing, U., 1 Jun 2017, In : American Journal of Hematology. 92, 6, p. 508-514 7 p.

Research output: Contribution to journalArticle

11 Citations (Scopus)

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome

Singhal, D., Kutyna, M. M., Chhetri, R., Wee, L. Y. A., Hague, S., Nath, L., Nath, S. V., Sinha, R., Wickham, N., Lewis, I. D., Ross, D. M., Bardy, P. G., To, L. B., Reynolds, J., Wood, E. M., Roxby, D. J. & Hiwase, D., 30 Nov 2017, In : Haematologica. 102, 12, p. 2021-2029 9 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1

Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., Buonamici, S., Hassan, A. Q., Lombardo, F., Iyer, V., Palmer, M., Berellini, G., Dodd, S., Thohan, S., Bitter, H., Branford, S. & 8 others, Ross, D. M., Hughes, T. P., Petruzzelli, L., Vanasse, K. G., Warmuth, M., Hofmann, F., Keen, N. J. & Sellers, W. R., 30 Mar 2017, In : Nature. 543, 7647, p. 733-737 5 p.

Research output: Contribution to journalArticle

153 Citations (Scopus)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study

Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V., Gattermann, N., Wiktor-Jedrzejczak, W., Le Coutre, P. D., Martino, B., Saussele, S., Menssen, H. D., Deng, W., Krunic, N., Bedoucha, V. & Saglio, G., 1 Jul 2017, In : Leukemia. 31, 7, p. 1525-1531 7 p.

Research output: Contribution to journalArticle

122 Citations (Scopus)
2016

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia

Latham, S., Bartley, P. A., Budgen, B., Ross, D. M., Hughes, E., Branford, S., White, D., Hughes, T. P. & Morley, A. A., Sep 2016, In : Journal of Clinical Pathology. 69, 9, p. 817-821 5 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Novel protein C gene mutation in a compound heterozygote resulting in catastrophic thrombosis in early adulthood: Diagnosis and long-term treatment with subcutaneous protein C concentrate

Boey, J. P., Jolley, A., Nicholls, C., Lerda, N., Duncan, E., Gallus, A., Ross, D. & Sobieraj-Teague, M., 1 Mar 2016, In : British Journal of Haematology. 172, 5, p. 811-813 3 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)
2015

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia

Bartley, P. A., Latham, S., Budgen, B., Ross, D. M., Hughes, E., Branford, S., White, D., Hughes, T. P. & Morley, A. A., 1 Jan 2015, In : Journal of Molecular Diagnostics. 17, 2, p. 185-192 8 p.

Research output: Contribution to journalArticle

16 Citations (Scopus)

Practical management of myelofibrosis with ruxolitinib

Ho, P. J., Marlton, P., Tam, C., Stevenson, W., Ritchie, D., Bird, R., Dunlop, L. C., Durrant, S. & Ross, D. M., 1 Dec 2015, In : Internal Medicine Journal. 45, 12, p. 1221-1230 10 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

TIDEL-Ii: First-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Braley, J., Herschtal, A., Kornhauser, M., Issa, S., Hiwase, D. K., Hertzberg, M., Schwarer, A. P., Filshie, R., Arthur, C. K., Kwan, Y. L., Trotman, J., Forsyth, C. J., Taper, J., Ross, D. M., Beresford, J., Tam, C. & 3 others, Mills, A. K., Grigg, A. P. & Hughes, T. P., 5 Feb 2015, In : Blood. 125, 6, p. 915-923 9 p.

Research output: Contribution to journalArticle

62 Citations (Scopus)
2014
36 Citations (Scopus)

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Cheah, C. Y., Burbury, K., Apperley, J. F., Huguet, F., Pitini, V., Gardembas, M., Ross, D. M., Forrest, D., Genet, P., Rousselot, P., Patton, N., Smith, G., Dunbar, C. E., Ito, S., Aguiar, R. C. T., Odenike, O., Gimelfarb, A., Cross, N. C. P. & Seymour, J. F., 5 Jun 2014, In : Blood. 123, 23, p. 3574-3577 4 p.

Research output: Contribution to journalArticle

72 Citations (Scopus)

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Branford, S., Yeung, D. T., Parker, W. T., Roberts, N. D., Purins, L., Braley, J. A., Altamura, H. K., Yeoman, A. L., Georgievski, J., Jamison, B. A., Phillis, S., Donaldson, Z., Leong, M., Fletcher, L., Seymour, J. F., Grigg, A. P., Ross, D. M. & Hughes, T. P., 24 Jul 2014, In : Blood. 124, 4, p. 511-518 8 p.

Research output: Contribution to journalArticle

125 Citations (Scopus)
2013

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

Branford, S., Yeung, D. T., Ross, D. M., Prime, J. A., Field, C. R., Altamura, H. K., Yeoman, A. L., Georgievski, J., Jamison, B. A., Phillis, S., Sullivan, B., Briggs, N. E., Hertzberg, M., Seymour, J. F., Reynolds, J. & Hughes, T. P., 9 May 2013, In : Blood. 121, 19, p. 3818-3824 7 p.

Research output: Contribution to journalArticle

97 Citations (Scopus)

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study

Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., Mills, A. K., Melo, J. V., White, D. L., Grigg, A. P. & Hughes, T. P., 25 Jul 2013, In : Blood. 122, 4, p. 515-522 8 p.

Research output: Contribution to journalArticle

445 Citations (Scopus)
2012

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: Implications for monitoring and management

Branford, S., Yeung, D. T., Prime, J. A., Choi, S. Y., Bang, J. H., Park, J. E., Kim, D. W., Ross, D. M. & Hughes, T. P., 3 May 2012, In : Blood. 119, 18, p. 4264-4271 8 p.

Research output: Contribution to journalArticle

29 Citations (Scopus)
2011

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

Ross, D. M., Bartley, P. A., Goyne, J., Morley, A. A., Seymour, J. F. & Grigg, A. P., 1 Nov 2011, In : Haematologica. 96, 11, p. 1720-1722 3 p.

Research output: Contribution to journalArticle

22 Citations (Scopus)
2010

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Bartley, P. A., Slader, C., Field, C., Dang, P., Filshie, R. J., Mills, A. K., Grigg, A. P., Melo, J. V. & Hughes, T. P., Oct 2010, In : Leukemia. 24, 10, p. 1719-1724 6 p.

Research output: Contribution to journalArticle

208 Citations (Scopus)

Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia: Research paper

Bartley, P. A., Martin-Harris, M. H., Budgen, B. J., Ross, D. & Morley, A. A., 1 Apr 2010, In : British Journal of Haematology. 149, 2, p. 231-236 6 p.

Research output: Contribution to journalArticle

17 Citations (Scopus)

Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA

Bartley, P. A., Ross, D. M., Latham, S., Martin-Harris, M. H., Budgen, B., Wilczek, V., Branford, S., Hughes, T. P. & Morley, A. A., Dec 2010, In : International Journal of Laboratory Hematology. 32, 6 PART 1

Research output: Contribution to journalArticle

43 Citations (Scopus)
2008

Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders

Ross, D. M. & Hughes, T., 1 Jan 2008, In : Pathology. 40, 3, p. 231-246 16 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)
2007

Acute myeloid leukaemia presenting as galactorrhoea

Muslahi, M. A. & Ross, D., 1 Oct 2007, In : International Journal of Laboratory Hematology. 29, 5, p. 390-392 3 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)
2006

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL

Ross, D. M., Branford, S., Moore, S. & Hughes, T., 1 Jan 2006, In : Leukemia. 20, 4, p. 664-670 7 p.

Research output: Contribution to journalArticle

56 Citations (Scopus)